Meeder Asset Management Inc Apellis Pharmaceuticals, Inc. Transaction History

Meeder Asset Management Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$30.74 - $49.16 $80,784 - $129,192	-2,628 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$31.4 - $69.84 $29,892 - $66,487	952 Added 56.8%	2,628 $87,000
Q2 2021 Aug 09, 2021	SELL	$40.9 - $64.9 $103,517 - $164,261	-2,531 Reduced 60.16%	1,676 $106,000
Q1 2021 Apr 28, 2021	BUY	$40.8 - $57.39 $171,645 - $241,439	4,207 New	4,207 $180,000
Q3 2020 Nov 02, 2020	SELL	$25.89 - $33.65 $121,501 - $157,919	-4,693 Closed	0 $0
Q2 2020 Aug 11, 2020	BUY	$24.8 - $38.49 $67,580 - $104,885	2,725 Added 138.47%	4,693 $153,000
Q1 2020 May 15, 2020	SELL	$17.91 - $44.33 $30,214 - $74,784	-1,687 Reduced 46.16%	1,968 $53,000
Q4 2019 Feb 13, 2020	BUY	$22.1 - $30.8 $74,256 - $103,488	3,360 Added 1138.98%	3,655 $112,000
Q3 2019 Oct 17, 2019	SELL	$24.09 - $32.18 $3,733 - $4,987	-155 Reduced 34.44%	295 $7,000
Q1 2019 Apr 16, 2019	BUY	$12.81 - $19.82 $140 - $218	11 Added 2.51%	450 $9,000
Q4 2018 Jan 17, 2019	BUY	$11.47 - $18.71 $5,035 - $8,213	439 New	439 $5,000
Q3 2018 Nov 02, 2018	SELL	$16.57 - $21.03 $2,203 - $2,796	-133 Closed	0 $0
Q2 2018 Jul 24, 2018	BUY	$19.63 - $30.0 $2,610 - $3,990	133 New	133 $0

309

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.79B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.